These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17502466)

  • 41. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
    Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
    Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spotlight on rotigotine transdermal patch in Parkinson's disease.
    Sanford M; Scott LJ
    Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
    Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
    Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rotigotine: in Parkinson's disease.
    Reynolds NA; Wellington K; Easthope SE
    CNS Drugs; 2005; 19(11):973-81. PubMed ID: 16268667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
    Güldenpfennig WM; Poole KH; Sommerville KW; Boroojerdi B
    Clin Neuropharmacol; 2005; 28(3):106-10. PubMed ID: 15965307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.
    Hening WA; Allen RP; Ondo WG; Walters AS; Winkelman JW; Becker P; Bogan R; Fry JM; Kudrow DB; Lesh KW; Fichtner A; Schollmayer E;
    Mov Disord; 2010 Aug; 25(11):1675-83. PubMed ID: 20629075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
    Valldeoriola F; Salvador A; Gómez-Arguelles JM; Marey J; Moya M; Ayuga Á; Ramírez F
    Int J Neurosci; 2018 Apr; 128(4):369-375. PubMed ID: 29249180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study.
    Inoue Y; Shimizu T; Hirata K; Uchimura N; Ishigooka J; Oka Y; Ikeda J; Tomida T; Hattori N;
    Sleep Med; 2013 Nov; 14(11):1085-91. PubMed ID: 24055212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
    Isaacson SH; Boroojerdi B; Waln O; McGraw M; Kreitzman DL; Klos K; Revilla FJ; Heldman D; Phillips M; Terricabras D; Markowitz M; Woltering F; Carson S; Truong D
    Parkinsonism Relat Disord; 2019 Jul; 64():132-137. PubMed ID: 30948242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
    Bauer A; Cassel W; Benes H; Kesper K; Rye D; Sica D; Winkelman JW; Bauer L; Grieger F; Joeres L; Moran K; Schollmayer E; Whitesides J; Carney HC; Walters AS; Oertel W; Trenkwalder C;
    Neurology; 2016 May; 86(19):1785-93. PubMed ID: 27164714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
    Baldwin CM; Keating GM
    CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
    Ghys L; Surmann E; Whitesides J; Boroojerdi B
    Expert Opin Pharmacother; 2011 Sep; 12(13):1985-98. PubMed ID: 21790503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Notice of redundant publication: "Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease" (Arch Neurol. 2007;64[5]:676-682).
    Rosenberg R
    Arch Neurol; 2007 Dec; 64(12):1800-1; author reply 1801. PubMed ID: 18071051
    [No Abstract]   [Full Text] [Related]  

  • 59. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
    Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
    Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
    Woitalla D; Kassubek J; Timmermann L; Lauterbach T; Berkels R; Grieger F; Müller T
    Parkinsonism Relat Disord; 2015 Mar; 21(3):199-204. PubMed ID: 25595315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.